📊 AMRN Key Takeaways
Is Amarin Corp. Plcuk (AMRN) a Good Investment?
Amarin faces significant operational challenges with negative operating margins of -23.5% and persistent net losses despite a 56.6% gross margin, indicating substantial R&D and operating expense burdens that are unsustainable. Declining revenue (-6.5% YoY) combined with negative profitability metrics (ROE: -8.4%, ROA: -5.8%) and minimal free cash flow generation (3.0% FCF margin) suggest deteriorating business fundamentals. While the company maintains adequate liquidity (3.34x current ratio) and zero long-term debt, the trajectory of profitability deterioration and revenue contraction poses meaningful risk to long-term viability.
Amarin's fundamentals show a mixed but overall weak profile: revenue is declining, margins remain deeply negative, and the business is still unprofitable at both the operating and net income levels. The main offset is a very strong balance sheet with no long-term debt, ample liquidity, and slightly positive free cash flow, but that financial strength does not yet compensate for poor earnings quality and limited growth momentum.
Why Buy Amarin Corp. Plcuk Stock? AMRN Key Strengths
- Strong balance sheet with $134.7M cash and zero long-term debt providing financial flexibility
- Solid current ratio of 3.34x and quick ratio of 2.33x indicating adequate short-term liquidity
- Healthy 56.6% gross margin demonstrating product pricing power despite operational losses
- Strong liquidity with a 3.34x current ratio and $134.66M in cash
- Debt-free balance sheet provides flexibility and lowers financial risk
- Positive operating cash flow and free cash flow indicate the business is not currently cash-burning on a core basis
AMRN Stock Risks: Amarin Corp. Plcuk Investment Risks
- Negative operating margin of -23.5% and net margin of -18.2% indicate unsustainable business model with operating losses continuing to exceed gross profits
- Revenue declining 6.5% year-over-year suggesting loss of market share or demand weakness in pharmaceutical segment
- Minimal free cash flow generation (3.0% FCF margin) combined with operating losses raises concerns about cash runway sustainability despite current cash reserves
- Negative ROE (-8.4%) and ROA (-5.8%) indicating shareholder value destruction and inefficient asset utilization
- Revenue declined 6.5% year over year, signaling weak top-line momentum
- Operating and net margins remain negative, showing the business model is not yet sustainably profitable
- Returns on equity and assets are negative, indicating inefficient use of capital
Key Metrics to Watch
- Revenue trajectory and stabilization of YoY decline rate
- Operating margin improvement toward breakeven through cost control
- Operating cash flow sustainability and free cash flow generation
- Cash burn rate relative to current cash reserves and runway
- Revenue growth trend and ability to stabilize or reaccelerate sales
- Operating margin and free cash flow consistency
Amarin Corp. Plcuk (AMRN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 3.0% FCF margin may limit capital allocation flexibility. Strong liquidity with a 3.34x current ratio provides a solid financial cushion.
AMRN Profit Margin, ROE & Profitability Analysis
AMRN vs Healthcare Sector: How Amarin Corp. Plcuk Compares
How Amarin Corp. Plcuk compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Amarin Corp. Plcuk Stock Overvalued? AMRN Valuation Analysis 2026
Based on fundamental analysis, Amarin Corp. Plcuk has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Amarin Corp. Plcuk Balance Sheet: AMRN Debt, Cash & Liquidity
AMRN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Amarin Corp. Plcuk's revenue has declined by 50% over the 5-year period, indicating business contraction. The most recent EPS of $-0.15 indicates the company is currently unprofitable.
AMRN Revenue Growth, EPS Growth & YoY Performance
AMRN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $42.3M | $1.5M | $-0.02 |
| Q2 2025 | $67.5M | $1.5M | $0.00 |
| Q1 2025 | $42.0M | -$10.0M | $-0.02 |
| Q3 2024 | $42.3M | $1.5M | $-0.05 |
| Q2 2024 | $67.5M | $1.5M | $0.00 |
| Q1 2024 | $56.5M | -$10.0M | $-0.02 |
| Q3 2023 | $66.1M | -$5.1M | $-0.01 |
| Q2 2023 | $80.2M | -$16.5M | $-0.04 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Amarin Corp. Plcuk Dividends, Buybacks & Capital Allocation
AMRN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Amarin Corp. Plcuk (CIK: 0000897448)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AMRN
What is the AI rating for AMRN?
Amarin Corp. Plcuk (AMRN) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AMRN's key strengths?
Claude: Strong balance sheet with $134.7M cash and zero long-term debt providing financial flexibility. Solid current ratio of 3.34x and quick ratio of 2.33x indicating adequate short-term liquidity. ChatGPT: Strong liquidity with a 3.34x current ratio and $134.66M in cash. Debt-free balance sheet provides flexibility and lowers financial risk.
What are the risks of investing in AMRN?
Claude: Negative operating margin of -23.5% and net margin of -18.2% indicate unsustainable business model with operating losses continuing to exceed gross profits. Revenue declining 6.5% year-over-year suggesting loss of market share or demand weakness in pharmaceutical segment. ChatGPT: Revenue declined 6.5% year over year, signaling weak top-line momentum. Operating and net margins remain negative, showing the business model is not yet sustainably profitable.
What is AMRN's revenue and growth?
Amarin Corp. Plcuk reported revenue of $213.6M.
Does AMRN pay dividends?
Amarin Corp. Plcuk does not currently pay dividends.
Where can I find AMRN SEC filings?
Official SEC filings for Amarin Corp. Plcuk (CIK: 0000897448) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AMRN's EPS?
Amarin Corp. Plcuk has a diluted EPS of $-0.09.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is AMRN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Amarin Corp. Plcuk has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is AMRN stock overvalued or undervalued?
Valuation metrics for AMRN: ROE of -8.4% (sector avg: 15%), net margin of -18.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy AMRN stock in 2026?
Our dual AI analysis gives Amarin Corp. Plcuk a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AMRN's free cash flow?
Amarin Corp. Plcuk's operating cash flow is $6.7M, with capital expenditures of $252.0K. FCF margin is 3.0%.
How does AMRN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -18.2% (avg: 12%), ROE -8.4% (avg: 15%), current ratio 3.34 (avg: 2).